[1]马永华,唐育斌.归芪三七口服液联合恩替卡韦在HBV相关性肝癌经动脉栓塞化疗中的临床应用价值[J].西部中医药,2013,26(12):97-98.
 MA Yonghua,TANG Yubin.Clinical Application Value of GuiQi SanQi Oral Liquid and Entecavir Tablets to Transcatheter Arterial Chemoembolization in Treating HBV Related Hepatocellular Carcinoma[J].Western Journal of Traditional Chinese Medicine,2013,26(12):97-98.
点击复制

归芪三七口服液联合恩替卡韦在HBV相关性肝癌经动脉栓塞化疗中的临床应用价值
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
26
期数:
2013年12期
页码:
97-98
栏目:
出版日期:
2013-12-15

文章信息/Info

Title:
Clinical Application Value of GuiQi SanQi Oral Liquid and Entecavir Tablets to Transcatheter Arterial Chemoembolization in Treating HBV Related Hepatocellular Carcinoma
文章编号:
1004-6852(2013)12-0097-02
作者:
马永华唐育斌
嘉峪关市第二人民医院,甘肃 嘉峪关 735100
Author(s):
MA Yonghua, TANG Yubin
Jiayuguan Municipal the Second People′s Hospital, Jiayuguan 735100, China
关键词:
肝癌经动脉栓塞化疗归芪三七口服液恩替卡韦片
Keywords:
transcatheter arterial chemoembolization (TACE) GuiQi SanQi oral liquid entecavir tablets
分类号:
R735.7
文献标志码:
B
摘要:
目的:探讨归芪三七口服液联合恩替卡韦(ETV)在HBV相关性肝癌经动脉栓塞化疗(TACE)中的临床应用价值。方法:将80例患者随机分为对照组与治疗组各40例,2组均在行TACE治疗前始给予恩替卡韦治疗,治疗组在恩替卡韦治疗的同时加用归芪三七口服液治疗,行TACE治疗后1月监测血常规、肝脏功能、HBV DNA定量的变化情况。结果:治疗组血常规、肝脏功能的改善情况明显优于对照组(P<0.05),但HBV DNA定量2组无明显差异(P>0.05)。结论:归芪三七口服液联合恩替卡韦在HBV相关性肝癌行TACE治疗后,可以降低肝脏损害的严重程度,预防肝功能的进一步恶化。
Abstract:
Objective: To explore clinical application value of GuiQi SanQi oral liquid and entecavir tablets to transcatheter arterial chemoembolization (TACE) in treating HBV related hepatocellular carcinoma. Method: All 80 patients were randomized into the control group and the treatment group. Both groups took entecavir tablets before TACE was performed, and the treatment group were also given with GuiQi SanQi oral liquid, routine blood test, liver function and quantitative HBV DNA were monitored after TACE was performed in one month. Result: The improvements of routine blood test and liver function in the treatment group were superior to these of the control group (P<0.05), but the comparison between both groups had insignificant difference in quantitative HBV DNA. Conclusion: GuiQi SanQi oral liquid and entecavir could reduce the severity of liver damage and prevent further deterioration of liver function in treating HBV related hepato cellular carcinoma.

备注/Memo

备注/Memo:
收稿日期:2013-05-14。作者简介:马永华(1970—),男,主治医师。研究方向:消化道肿瘤的中西医诊治。
更新日期/Last Update: 2013-12-15